Mavacamten
Pre-clinicalActive 0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Conditions
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Trial Timeline
Dec 22, 2023 → Dec 31, 2025
NCT ID
NCT07107373About Mavacamten
Mavacamten is a pre-clinical stage product being developed by Bristol Myers Squibb for Obstructive Hypertrophic Cardiomyopathy (oHCM). The current trial status is active. This product is registered under clinical trial identifier NCT07107373. Target conditions include Obstructive Hypertrophic Cardiomyopathy (oHCM).
What happened to similar drugs?
20 of 20 similar drugs in Obstructive Hypertrophic Cardiomyopathy (oHCM) were approved
Approved (20) Terminated (2) Active (0)
✅Arformoterol Tartrate Inhalation Solution + Arformoterol Tartrate Inhalation Solution + PlaceboSumitomo PharmaApproved
Hype Score Breakdown
Clinical
3
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (19)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07361289 | Pre-clinical | Recruiting |
| NCT07004972 | Approved | Recruiting |
| NCT07383025 | Pre-clinical | Recruiting |
| NCT06146660 | Pre-clinical | Recruiting |
| NCT06338202 | Pre-clinical | Completed |
| NCT06551129 | Pre-clinical | Recruiting |
| NCT06549608 | Pre-clinical | Active |
| NCT06112743 | Approved | Active |
| NCT07107373 | Pre-clinical | Active |
| NCT05939700 | Pre-clinical | Recruiting |
| NCT06023186 | Pre-clinical | Recruiting |
| NCT07168655 | Pre-clinical | Completed |
| NCT05719805 | Phase 1 | Completed |
| NCT05582395 | Phase 3 | Completed |
| NCT05414175 | Phase 3 | Completed |
| NCT05362045 | Phase 1 | Completed |
| NCT04766892 | Phase 2 | Completed |
| NCT03723655 | Phase 2/3 | Completed |
| NCT03496168 | Phase 2 | Completed |
Competing Products
20 competing products in Obstructive Hypertrophic Cardiomyopathy (oHCM)